Patients to benefit from updated skin tumour publications
26 October 2018
Healthcare professionals specialising in skin cancers, including melanoma, now have access to two publications with the most current information relating to skin tumour diagnosis and management. Both publications – the WHO Classification of Skin Tumours, 4th Edition, and Pathology of Melanocytic Tumours – are co-edited by Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia (MIA), and will have a major impact on the diagnosis and management of melanoma and other skin tumours.
The WHO Classification of Skin Tumours, 4th Edition integrates diagnostic information and pathological features of skin tumours with the latest in molecular, genetic and epidemiological information. This edition of the WHO Skin Blue Book has substantially updated the classification of melanoma and is a breakthrough publication that every pathologist, dermatopathologist, dermatologist, oncologist and other health care professionals who deal with skin tumours should have.
A separate textbook Professor Scolyer has edited with other world authorities from the USA is Pathology of Melanocytic Tumours. Constituting a large percentage of everyday diagnostic practice, melanocytic pathology is a complex and challenging area with many difficult-to-diagnose lesions. This highly illustrated reference, written by three of the world’s leading dermatopathologists, provides authoritative guidance in the accurate diagnosis of even the most challenging pigmented skin tumours.
‘These publications will undoubtedly assist the care of patients with melanoma and other skin cancers world-wide,” Professor Scolyer said.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.